JP2013538849A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538849A5
JP2013538849A5 JP2013531533A JP2013531533A JP2013538849A5 JP 2013538849 A5 JP2013538849 A5 JP 2013538849A5 JP 2013531533 A JP2013531533 A JP 2013531533A JP 2013531533 A JP2013531533 A JP 2013531533A JP 2013538849 A5 JP2013538849 A5 JP 2013538849A5
Authority
JP
Japan
Prior art keywords
naloxol
polyethylene glycol
mpeg
glycol conjugate
oxalate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013531533A
Other languages
English (en)
Japanese (ja)
Other versions
JP6034789B2 (ja
JP2013538849A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2011/051161 external-priority patent/WO2012044243A1/en
Publication of JP2013538849A publication Critical patent/JP2013538849A/ja
Publication of JP2013538849A5 publication Critical patent/JP2013538849A5/ja
Application granted granted Critical
Publication of JP6034789B2 publication Critical patent/JP6034789B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013531533A 2010-09-30 2011-09-29 結晶性ナロキソール−peg接合体 Active JP6034789B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38850110P 2010-09-30 2010-09-30
US61/388,501 2010-09-30
PCT/SE2011/051161 WO2012044243A1 (en) 2010-09-30 2011-09-29 Crystalline naloxol-peg conjugate

Publications (3)

Publication Number Publication Date
JP2013538849A JP2013538849A (ja) 2013-10-17
JP2013538849A5 true JP2013538849A5 (enExample) 2016-02-18
JP6034789B2 JP6034789B2 (ja) 2016-11-30

Family

ID=45893441

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013531533A Active JP6034789B2 (ja) 2010-09-30 2011-09-29 結晶性ナロキソール−peg接合体

Country Status (39)

Country Link
US (2) US9012469B2 (enExample)
EP (2) EP2992903B8 (enExample)
JP (1) JP6034789B2 (enExample)
KR (1) KR101791724B1 (enExample)
CN (1) CN103237547B (enExample)
AR (1) AR083268A1 (enExample)
AU (1) AU2011307608B8 (enExample)
BR (1) BR112013007113B1 (enExample)
CA (1) CA2812649C (enExample)
CL (1) CL2013000866A1 (enExample)
CO (1) CO6700851A2 (enExample)
CR (1) CR20130146A (enExample)
CU (1) CU24317B1 (enExample)
DK (1) DK2621496T4 (enExample)
EA (1) EA023929B1 (enExample)
EC (1) ECSP13012531A (enExample)
ES (2) ES2562643T5 (enExample)
GT (1) GT201300084A (enExample)
HR (1) HRP20151420T4 (enExample)
HU (1) HUE026726T2 (enExample)
IL (1) IL225308A0 (enExample)
ME (1) ME02313B (enExample)
MX (1) MX2013003587A (enExample)
MY (1) MY173890A (enExample)
NI (1) NI201300034A (enExample)
NZ (1) NZ609874A (enExample)
PE (1) PE20140636A1 (enExample)
PH (1) PH12013500561A1 (enExample)
PL (1) PL2621496T5 (enExample)
PT (1) PT2621496E (enExample)
RS (1) RS54488B8 (enExample)
SA (1) SA111320808B1 (enExample)
SG (1) SG188474A1 (enExample)
SI (1) SI2621496T2 (enExample)
SM (1) SMT201600004B (enExample)
TW (1) TWI518088B (enExample)
UA (1) UA112847C2 (enExample)
UY (1) UY33643A (enExample)
WO (1) WO2012044243A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023929B1 (ru) 2010-09-30 2016-07-29 Астразенека Аб Кристаллический конъюгат налоксол-peg
WO2014070745A1 (en) * 2012-10-30 2014-05-08 Nektar Therapeutics Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
CA2977732C (en) * 2015-03-10 2021-02-23 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
CN107033154B (zh) 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN107033155B (zh) * 2016-02-04 2019-04-26 国药集团国瑞药业有限公司 一种吗啡酮类化合物的立体选择性还原方法
EP3228307A1 (en) 2016-04-05 2017-10-11 Sandoz Ag Solid dispersion comprising opioid antagonists
CN107303392A (zh) * 2016-04-19 2017-10-31 石家庄蒎格医药科技有限公司 一种聚乙二醇-纳洛酮组合物及应用
WO2018096464A1 (en) * 2016-11-23 2018-05-31 Aurobindo Pharma Limited Naloxegol oxalate and solid dispersion thereof
US11373198B2 (en) * 2016-12-02 2022-06-28 Honda Motor Co., Ltd. Evaluation device, evaluation method, and evaluation program
WO2019058387A1 (en) * 2017-09-19 2019-03-28 Msn Laboratories Private Limited, R&D Center IMPROVED PROCESS FOR THE PREPARATION OF (5Α, 6Α) -17-ALLYL-6- (2,5,8,11,14,17,20-HEPTAOXADOCOSAN-22-YLOXY) -4,5-EPOXYMORPHINANE-3,14-DIOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
KR20230005928A (ko) * 2020-05-04 2023-01-10 오츠카 세이야쿠 가부시키가이샤 Iap 길항제 화합물 및 중간체 및 이를 합성하는 방법
CN114137133B (zh) * 2021-12-03 2023-06-09 北京尚修堂医药科技有限公司 一种纳洛醇-peg衍生物有关物质的检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507136A (en) 1949-02-19 1950-05-09 New York Quinine And Chemical Alkaloid purification
JPH08504189A (ja) * 1992-09-21 1996-05-07 キン、ボーイ 低/非たんでき性オピオイド鎮痛剤の確認及び使用方法
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
DE60026073T2 (de) 1999-12-22 2006-09-28 Nektar Therapeutics Al, Corp., Huntsville Sterisch gehinderte derivate von wasserlöslichen polymeren
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
AU2002217981A1 (en) 2000-11-30 2002-06-11 Cornerstone Pharmaceuticals, Inc. Water-soluble polymer conjugates of triazine derivatives
ATE337313T1 (de) 2000-12-22 2006-09-15 Smithkline Beecham Plc 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy)benzyl)thiazolidin-2,4-dion mesylatsalz
EP1362053B1 (en) 2001-02-20 2007-11-14 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6756354B2 (en) 2001-09-05 2004-06-29 Deanna Jean Nelson Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates
EP1436012B1 (en) 2001-10-18 2017-12-20 Nektar Therapeutics Polymer conjugates of opioid antagonists
KR20050040832A (ko) 2001-10-29 2005-05-03 넥타르 테라퓨틱스 에이엘, 코포레이션 단백질 키나아제 c 억제제의 중합체 공액
JP2005507934A (ja) 2001-10-30 2005-03-24 ネクター セラピューティックス エイエル,コーポレイション レチノイン酸の水溶性ポリマー結合体
DE60325567D1 (de) * 2002-04-05 2009-02-12 Euro Celtique Sa Matrix für die modifizierte freigabe von aktiven substanzen
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
CA2547140A1 (en) 2003-11-24 2005-06-09 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
EP2905033B1 (en) 2003-12-16 2020-09-02 Nektar Therapeutics Monodisperse PEGylated naloxol compositions
US8320574B2 (en) * 2006-04-20 2012-11-27 Hewlett-Packard Development Company, L.P. Methods and systems for reducing acoustic echoes in communication systems
WO2007124114A2 (en) 2006-04-21 2007-11-01 Nektar Therapeutics Al, Corporation Stereoselective reduction of a morphinone
US20100284960A1 (en) * 2006-11-07 2010-11-11 Nektar Therapeutics Al, Corporation Dosage Forms and Co-Administration of Opioid Agonist and Opioid Antagonist
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
WO2009137086A1 (en) 2008-05-07 2009-11-12 Nektar Therapeutics Oral administration of peripherally-acting opioid antagonists
AU2010276244B2 (en) 2009-07-21 2015-08-13 Nektar Therapeutics Oligomer-opioid agonist conjugates
EA023929B1 (ru) 2010-09-30 2016-07-29 Астразенека Аб Кристаллический конъюгат налоксол-peg

Similar Documents

Publication Publication Date Title
JP2013538849A5 (enExample)
JP2014501282A5 (enExample)
JP2021530565A5 (enExample)
JP2020512316A5 (enExample)
JP2010516681A5 (enExample)
JP2012527442A5 (enExample)
JP2009537603A (ja) 5−アミノ−3−(2’,3’−ジ−O−アセチル−ベータ−D−リボフラノシル)−3H−チアゾロ[4,5−d]ピリミジン−2−オンのマレイン酸塩のA型及びB型結晶形
CN1227233C (zh) 纯晶形的5-氯-3-(4-甲磺酰基苯基)-6′-甲基-[2,3′]联吡啶及其合成方法
JP2014524442A5 (enExample)
JP2019504103A5 (enExample)
JP2012532106A5 (enExample)
JP2010519300A5 (enExample)
JP2016510768A5 (enExample)
JP2013517320A5 (enExample)
JP2009040767A5 (enExample)
JP2012512145A (ja) フリバンセリンの結晶性の塩形態
US10351574B2 (en) Pharmaceutically acceptable salts and polymorphic forms of hydrocodone benzoic acid enol ester and processes for making same
JP2013541589A5 (enExample)
JP2015531354A5 (enExample)
CA2794389A1 (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
JP2019524829A5 (enExample)
RU2005105688A (ru) Полиморфизм додекагидроциклопента (а) фенантренилового эфира тиофенкарбоновой кислоты
JP2019500385A5 (enExample)
JP2014506230A5 (enExample)
JP2010540440A5 (enExample)